Barriers to Lung Cancer Screening Access from the Perspective of the Patient and Current Interventions

Factors Influencing Willingness to Undergo Lung Cancer Screening in the Future: A Cross-Sectional Study of Japanese University Students

“…The term "cancer screening experience" in this context referred to voluntary cancer screening, distinct from any general health checkups that participants receive at school or other institutions. In order to ensure the validity of the questions, the present study was based on previous research [12,13], and questions regarding knowledge and perception of LC and LCS, psychological factors, and cancer education experience were formulated to examine their potential influence on college students' intentions to receive LCSs. Specifically, participants were asked about their past experiences with and receptiveness towards cancer education, alongside their concerns about cancer.…”

“…Despite this, a previous Japanese study reported that current smokers were less likely to undergo LCS compared to non-smokers [11]. Other barriers to receiving LCS include cognitive factors such as limited information [12] and ignorance [13], access-related factors such as lack of recommendations by health care providers [12], psychological factors such as concerns about LC [12] and negative attitudes towards LCS outcomes [13], and the inconvenience associated with accessing LCSs [13]. The LCS process varies across countries owing to varying evidence [14].…”

“…Therefore, this study aimed to determine the inclination of college students towards undergoing LCS and the factors influencing it. In this study, we hypothesized that in addition to smoking history [11], knowledge of LC and LCS, and the psychological factors [12,13] identified in previous studies, other factors, including experience with cancer education, could influence college students' intentions to undergo LCS. Additionally, nicotine dependence [17] and the number of cigarettes smoked daily [11] are associated with smokers' participation in several cancer screening programs.…”

Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer

“…The current therapeutic strategies yield a disconcertingly low 5-year survival rate of less than 15% [ 1 , 2 ]. Standard treatment modalities for NSCLC encompass surgical resection, radiation therapy, chemotherapy, targeted therapy, and immunotherapy [ 3 ]. Although the primary goal of these treatments is curative, the late-stage diagnosis, coupled with the recurrence and resistance of the disease, presents significant obstacles to optimal NSCLC management [ 4 , 5 ].…”